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Abstract
To identify Huntington’s Disease therapeutics, we conducted high-content small molecule and RNAi suppressor screens
using a Drosophila primary neural culture Huntingtin model. Drosophila primary neurons offer a sensitive readout for
neurotoxicty, as their neurites develop dysmorphic features in the presence of mutant polyglutamine-expanded Huntingtin
compared to nonpathogenic Huntingtin. By tracking the subcellular distribution of mRFP-tagged pathogenic Huntingtin
and assaying neurite branch morphology via live-imaging, we identified suppressors that could reduce Huntingtin
aggregation and/or prevent the formation of dystrophic neurites. The custom algorithms we used to quantify neurite
morphologies in complex cultures provide a useful tool for future high-content screening approaches focused on
neurodegenerative disease models. Compounds previously found to be effective aggregation inhibitors in mammalian
systems were also effective in Drosophila primary cultures, suggesting translational capacity between these models.
However, we did not observe a direct correlation between the ability of a compound or gene knockdown to suppress
aggregate formation and its ability to rescue dysmorphic neurites. Only a subset of aggregation inhibitors could revert
dysmorphic cellular profiles. We identified lkb1, an upstream kinase in the mTOR/Insulin pathway, and four novel drugs,
Camptothecin, OH-Camptothecin, 18b-Glycyrrhetinic acid, and Carbenoxolone, that were strong suppressors of mutant
Huntingtin-induced neurotoxicity. Huntingtin neurotoxicity suppressors identified through our screen also restored viability
in an in vivo Drosophila Huntington’s Disease model, making them attractive candidates for further therapeutic evaluation.
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Introduction
Huntington’s Disease (HD) is a dominantly inherited fatal
neurodegenerative disorder. It results from expansion of a
polygluatamine (polyQ) tract in the Huntingtin (Htt) protein
which alters its conformation and function [1]. Neuropathological
hallmarks of the disease include Htt aggregation, early-onset
striatal neurodegeneration, and late-stage cortical thinning [2,3].
Mammalian models of HD indicate that neuron-specific dysreg-
ulation of cellular physiology contributes to the underlying
neuropathology, although subcortical white matter degeneration
may also suggest a glial contribution [4–7]. Mutant Htt has been
suggested to disrupt transcription, proteasome activity, axonal
transport, synaptic function, signaling cascades (including the
mTOR/Insulin pathway) and other physiological processes in a
variety of neuronal subtypes [8].
PolyQ tract length accounts for approximately 70% of the
variance in the age-of-onset of Huntington’s disease [9], with the
remaining variance attributed to disease-modifying agents such as
environmental factors or genetic background. Linkage analysis
using large affected families is the gold standard for identifying
disease modifying loci [10]. However, these investigations require
lengthy study periods and considerable resources. In vitro genetic or
chemical suppressor screens offer another avenue to rapidly
identify suppressors. The suitability of cell-based screening models
encompasses several considerations. Htt is ubiquitously expressed,
yet deleterious effects of mutant polyQ expansion are observed
primarily in the central nervous system of HD patients. In
conducting suppressor screens, it is therefore desirable to use
neuronal systems. Stable neuronal cell lines can change their
characteristics over continued passages, and thus may not retain
HD phenotypes. In addition, stable cell lines continually divide,
which may alter regulation of cell survival and death pathways that
are relevant to the human disease state in quiescent neurons.
Primary neuronal disease models have many advantages, since
cellular growth and differentiation states are more similar to the in
vivo situation, yet they are amenable to high-throughput chemical
and genetic suppressor screens.
Huntingtin is conserved in Drosophila, and orthologs of many
interacting proteins exist [11–13]. Suppressor screening with first
generation exon 1 Htt fragments has generated important
candidate disease modifying agents [14,15]. However, protein
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Htt pathogenesis, and therefore there is a need to conduct
additional screens using larger Htt constructs in more physiolog-
ically relevant systems [16]. To this end, we have developed a
Drosophila primary neural culture system for HD, using a large
human Htt fragment (exons 1–12, 588 amino acids in addition to
the polyQ tract). The methodology is suited to high throughput
small molecule and RNAi suppressor screening, and offers a
desirable balance between physiological relevance and technical
tractability.
We demonstrate that a 588 amino acid human Htt fragment
containing an expanded polyQ tract (138Q) readily forms
cytoplasmic aggregates in primary neurons, in addition to causing
aberrant neuronal morphology when compared to non-expanded
human Htt controls (15Q). From a screen of approximately 2600
small molecules and a whole genome kinase/phosphatase RNAi
library, we identified four new compounds that could revert the
mutant phenotype (Camptothecin, 10-Hydroxycamptothecin,
18b-Glycyrrhetinic acid, Carbenoxolone) and knockdown of the
lkb1 kinase, that can suppress polyQ Htt aggregation and revert
morphological profiles towards control states. In addition, we
identified several previously studied polyQ Htt aggregation
inhibitors. This Drosophila HD model represents an attractive
system for future large-scale suppressor screening. In addition, the
current candidates provide new avenues to define pathogenic
mechanisms in HD.
Results
Drosophila Primary Neural Culture Screening System for
Huntington’s Disease
We have previously described a Drosophila Huntington’s Disease
model which displays many characteristics of human HD,
including neurodegeneration, disrupted axonal transport, and
decreased longevity [17]. To extend our studies of HD pathology,
we generated a new monomeric Red Fluorescent Protein (mRFP)
N-terminal tag variant for in vivo imaging of Htt distribution (Htt-
RFP). The Htt-RFP construct encompasses the caspase-6 cleavage
fragment important for Htt toxicity [18] and includes either a non-
pathogenic (15Q) or pathogenic (138Q) polyQ tract. This
Figure 1. Confocal microscopy images of Htt15Q (A–C) and Htt138Q (D–F) expressing Drosophila primary neural cultures plated on
glass coverslips. The subcellular distribution of Htt (red channel), morphology of Htt expressing primary cultures (green channel, UAS-CD8GFP),
and merged images are shown. Htt15Q (B) has a diffuse cytoplasmic distribution and fills most processes of cultured neurons, while Htt138Q forms
large insoluble aggregates that accumulate in neurites and within cell bodies of neuromere clusters (E). Htt15Q and Htt138Q expressing cultures also
display different neuronal morphologies. Htt15Q cultures have long straight neurites (A), while Htt138Q cultures have shorter neurites that fail to
extend from neuromere clusters leading to a club-like appearance (B). (G) Quantitative Western blot (n=4) showing that the relative expression level
of Htt15Q
1 and Htt138Q
1 is comparable in strains used for primary culture screening (compare lanes 2 and 3). A Htt138Q strain with weaker
expression is also shown (lane 4, Htt138Q
2). The strain genotypes that are listed on the bar graph (left to right) correspond to lanes 1–4 of the blot.
Tubulin was used as a loading control. p,0.05. Scale bar: 100 mm.
doi:10.1371/journal.pone.0023841.g001
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amino acids in length (,80 kDa), excluding the polyQ domain
and RFP tag. For our studies, we used the GAL4/UAS system
[19] to drive expression of the constructs in the nervous system
using the pan-neuronal GAL4 driver Elav
c155 (C155). We selected
UAS-Htt15QmRFP and UAS-Htt138QmRFP strains that had
comparable expression levels (i.e. Htt15Q
1 and Htt138Q
1) when
crossed to C155 as demonstrated by quantitative Western blotting
(Figure 1G). Prominent bands of ,109 kDa and ,125 kDa were
observed for the Htt15Q
1 and Htt138Q
1 strains, respectively, in
agreement with the predicted molecular weights of the RFP-fusion
proteins. Pan-neuronal expression of Htt138Q
1 using C155 causes
pupal lethality, while Htt15Q
1 controls are viable and have normal
longevity (see detailed analysis below). For downstream behavioral
analysis, we selected an additional UAS-Htt138QmRFP strain
(Htt138Q
2) that has reduced Htt138Q protein expression
(Figure 1G) and is adult viable. The decreased longevity observed
in the Htt138Q
1 strain is more severe than that observed in our
earlier studies [17] and may be related to an increased polyQ
length in the new construct (138Q vs. 128Q), a larger Htt N-
terminal fragment (588 a.a. vs. 548 a.a.), or differences in Htt
expression levels. The severity of the Htt138Q
1 allele suggests that
this model may correspond to juvenile-onset HD observed in
humans [20]. In juvenille-onset HD, the CAG repeats often
exceed 55 and phenotypes develop prior to adulthood.
To conduct a small molecule and RNAi screen to identify
suppressors of Huntington toxicity we prepared primary neuronal
cultures from control (C155;Htt15QmRFP
1, abbreviated as Htt15Q)
and mutant (C155;UAS-Htt138QmRFP
1, abbreviated as Htt138Q)
Huntingtin strains that simultaneously expressed membrane
associated-GFP (UAS-CD8GFP) in all neurons. This dual labeling
approach enabled us to track the subcellular distribution of mRFP-
tagged Huntingtin, while simultaneously monitoring the general
morphology of cultured neurons (Fig. 1 A–F). Visualization of Htt-
RFP localization demonstrated that Htt138Q readily forms
aggregates which accumulate in cell bodies and neurites, while
Htt15Q is soluble and has a more uniform cytoplasmic
distribution (Fig. 1, compare 1B, 1E). In addition, we found that
Htt138Q-expressing neurons display morphological indicators of
reduced neuronal health [21,22], including smaller neuromeres,
increased branching, and reduced axonal connectivity, as
monitored by membrane associated-GFP (Fig. 1, compare 1A,
1D). Neurite morphology and Htt aggregation were quantified in
cultures plated in 384-well format using custom algorithms
developed to process digital images collected via automated
microscopy [23]. Population analysis of Htt15Q and Htt138Q
replicate wells revealed that eight morphology features (small,
medium, large, and average neuromere size, and short, medium,
long, and average neurite length) provided robust data content to
generate effective separation of Htt15Q control from Htt138Q
mutant neuronal morphology. Differences in Htt aggregation were
also readily detectable between mutant and control cultures using
these algorithms. To screen for suppressors of HD toxicity we
therefore monitored the presence of Htt aggregates, as well as
morphology, to evaluate overall neuron health.
Small Molecule/RNAi Suppressor Screens Using HD
Primary Cultures
We performed dual RNAi and small molecule screens to
identify HD toxicity suppressors, and assayed for suppression of
Htt138Q aggregate formation, in addition to reversion of mutant
Htt138Q morphology towards Htt15Q controls. For RNAi
screening, we wanted to identify novel targets for HD therapeutic
development, and focused on a kinase/phosphatase RNAi library
(468 genes) that would potentially contain targets of high value for
chemical inhibition. For small-molecule screening, we tested
libraries enriched for FDA-approved drugs, including the NINDS
Custom Collection 2, BIOMOL ICCB Known Bioactives
Collection and the Prestwick 1 Collection. This allowed screening
of <2600 approved compounds, potentially facilitating the
advancement of screen hits to clinical trials. For compound
screening, we verified that addition of 0.2% DMSO to primary
cultures does not significantly alter neuronal morphology or
Htt138Q aggregation characteristics (Table 1). Known suppressors
of Htt polyQ aggregation, including C2-8, GW5074, Juglone,
Radicicol, and Rapamycin, were tested for efficacy in our assay [24–
28]. Although all control compounds reduced Htt138Q aggrega-
tion, none reverted the morphology profiles of Htt138Q
expressing neurons towards Htt15Q controls (Table 1). Instead,
these compounds caused reduced axon outgrowth, neuromere
size, and suppressed GFP expression over a wide concentration
range, suggesting these compounds have neurotoxic properties.
To identify new potential therapeutic compounds that were not
neurotoxic,butthat were able to suppressmutant Htttoxicity inour
model, we conducted RNAi/compound screens in duplicate. All
wells were visually scored independently by two investigators to
identify agents that either suppressed aggregation, or reverted
mutant Htt138Q neural profiles towards Htt15Q controls. From
the visual-based screens, three novel suppressors of Htt polyQ
toxicity were identified: 1 RNAi hit (lkb1), and 2 compounds
(Camptothecin and 10-Hydroxycamptothecin). Lkb1 is a known
tumor suppressor and a negative regulator of the mTOR/Insulin
pathway, which has important roles in autophagy and nutrient
sensing [29,30], while the Camptothecins function as DNA
Topoisomerase 1 (Top1) inhibitors [31]. In addition to visual
inspection of the screen plates, automated microscopy was used to
record images of the compound-treated plates for subsequent
morphometric analysis using custom algorithms. For automated
microscopy, three images per well were taken at different sites for
each channel (GFP/RFP) to facilitate hit identification and increase
statistical power. Htt138Q aggregation was first quantified, leading
to the identification of 62 compounds that significantly suppressed
Htt aggregate formation (Fig. 2, Table S1). Subsequently, wells
where aggregate formation was inhibited were re-evaluated to
determineifanytreatmentswereable torevertthe mutant Htt138Q
morphology profiles towards that of Htt15Q controls. Of the 62
compounds that were found to inhibit Htt138Q aggregate
formation, 8 compounds were identified that improved the
Htt138Q induced morphological defects (Fig. 3A, Table 2).
Unmasking of the identities of the 8 compounds revealed that 4
compounds were Camptothecins, in agreement with the visual
scoring observations. In addition, two Na+/K+ ATPase inhibitors,
and a Glutathione-S-Transferase inhibitor were also identified as
being capable of suppressing aggregate formation and rescuing the
mutant Htt138Q culture morphologies towards the control state
(Table 2). We subsequently validated screen hits, focusing on the
targetsthat overlappedinboththe visual scoring and morphometric
computational analysis. The Lkb-1 target was validated with three
independent dsRNAs (amplicons DRSC16481, DRSC36925,
DRSC36926). Each amplicon improved Htt138Q mutant mor-
phology with statistical significance, but did not inhibit aggregate
formation (Table 3). The Camptothecin and 10-Hydroxy-campto-
thecin small molecules are structural analogues, and were found to
reduce aggregate formation in addition to partially reverting
dystrophic morphology profiles over a range of concentrations
(56 mM, 5.6 mM) (Fig. 4). These compounds alter Htt138Q
localization within neurons, such that it more closely resembles
the distribution of Htt15Q in control cultures (Fig. 4).
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To further examine the RNAi/small molecule screen hits, we
assayed in vivo efficacy by testing their ability to rescue lethality in
our Drosophila HD model. Htt138Q expression in the nervous
system results in late stage pupal lethality when animals are reared
on standard media. Animals undergo metamorphosis but fail to
eclose. In liquid culture, the longevity of the Htt138Q expressing
animals is reduced and larvae perish during the 2
nd instar stage,
likely due to drowning from decreased motility. Rapamycin, a well
characterized mTOR inhibitor [25], suppresses neurodegenera-
tion in various HD models, and we found it enhanced viability of
Htt138Q expressing larvae reared in liquid culture in a dose-
dependant fashion compared to DMSO-treated controls (Fig. 5A).
Using this assay, we found that Camptothecin and 10-Hydro-
xycamptothecin also increased larval longevity in vivo, but to a
lesser extent than Rapamycin (Fig. 5A). 10-Hydroxycamptothecin
is more efficacious than Camptothecin, possibly due to solubility
differences since Camptothecin readily precipitates when added to
cultures. Specific inhibitors of Lkb1 were not available for in vivo
testing. Given its role as an upstream regulatory kinase of the
mTOR/Insulin pathway, we tested additional pharmacological
agents that regulate this pathway, including Metformin (an
mTOR pathway activator and oral anti-diabetic drug) [32,33]
and 18b-Glycyrrhetinic acid (a putative mTOR inhibitor that acts
through PI3K/AKT) [34,35]. Metformin could not revert
Htt138Q-incuded lethality. However, 18b-Glycyrrhetinic acid
was almost as efficacious as Rapamycin (Fig. 5A). We also tested
an analogue of 18b-Glycyrrhetinic acid that has increased
solubility: Carbenoxolone, and found it to have comparable
activity. 18b-Glycyrrhetinic acid is non-toxic and has been used as
a commercial sweetener, making it an attractive candidate for
future studies for suppressive effects in mammalian HD models.
Rapamycin, in contrast, has numerous toxic side-effects that can
impact kidney and lung function, cause increased risk of infection,
and lead to hyperlipidemia [36–40].
To further examine the role of the Lkb1/Insulin pathway in the
suppression of HD toxicity, we conducted genetic interaction
studies with lkb1 loss-of-function mutations. While pan-neuronal
expression of Htt138Q
1 causes pupal lethality, the introduction of
a heterozygous lkb1 null mutation into the Htt138Q background
suppresses lethality. We observed no C155/+; UAS-Htt138Q/+
adult escapers at 25uC (n=83 pupae), however, the introduction
Table 1. Effect of positive control compounds on Htt138Q aggregate formation and neurite morphology (p-values listed) in
Drosophila primary neural culture system.
Compound CAS# Well Conc. (mM) Htt Culture
Mutant Htt 138Q
aggregation*
Mutant Htt138Q
morphology rescue** n=
C2-8 300670-16-0 2 138Q 0.0072745 06
C2-8 0.4 138Q 0.216406 0 6
C2-8 0.08 138Q 0.0679971 0 6
C2-8 0.016 138Q 0.381982 0 6
C2-8 0.0032 138Q 0.436453 0 6
GW5074 220904-83-6 2 138Q 0.000242646 06
GW5074 0.4 138Q 0.414394 0 6
GW5074 0.08 138Q 0.859258 0 6
GW5074 0.016 138Q 0.193046 0 6
GW5074 0.0032 138Q 0.062019 2.54 E-14 6
Juglone 481-39-0 100 138Q 0.00062262 0.00000361 6
Juglone 20 138Q 0.999965 0 6
Juglone 4 138Q 0.999994 0 6
Juglone 0.8 138Q 0.908447 0 6
Juglone 0.16 138Q 0.640557 1.26 E-11 6
Radicicol 12772-57-5 100 138Q 9.17E-66 06
Radicicol 20 138Q 0.0000587 06
Radicicol 4 138Q 0.671473 0 6
Radicicol 0.8 138Q 0.0313196 06
Radicicol 0.16 138Q 0.0116727 06
Rapamycin 53123-88-9 4 138Q 0.00161737 06
Rapamycin 0.8 138Q 0.134587 0 6
Rapamycin 0.16 138Q 0.151829 0 6
Rapamycin 0.032 138Q 0.382367 0 6
Rapamycin 0.0064 138Q 0.290667 0 6
DMSO 67-68-5 0.2% 138Q 1 0 360
DMSO 67-68-5 0.2% 15Q 0 1 144
*p,0.05 indicates Htt138Q aggregate formation is inhibited (bold, italics).
**p.0.05 indicates Htt138Q drug-treated culture have morphology similar to Htt15Q control cultures.
doi:10.1371/journal.pone.0023841.t001
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4B1-11/+ or Lkb1
4A4-2/+ allele into this background led to
an adult escaper frequency of 1.8% (n=110 pupae) and 3.7%
(n=81 pupae) respectively. Using quantitative Western blot
analysis, we found that the introduction of lkb1 trans-heterozygous
alleles does not reduce Htt138Q protein levels (Fig. 5D),
suggesting the suppressive effects are not tied to altering Htt
expression. This is in contrast to another rescuing deficiency we
identified in an independent screen, Df(3L)vin7, which significantly
decreases Htt138Q expression and yields an escaper frequency of
25.9% (n=85 pupae). The Lkb1 heterozygous animals expressing
Htt138Q are viable and have relatively normal walking ability,
although they do not inflate their wings (Fig. 5C, Movie S1). To
further investigate the relationship between lkb1 and mutant
Htt138Q toxicity, we introduced the Lkb1
4A4-2/+ allele into a
weaker Htt138Q expressing strain (C155/+; UAS-
Htt138QmRFP
2/+) which is adult viable so that we could
evaluate climbing behavior as an indicator of motor performance.
From negative geotaxis assays performed on 25-day old flies, we
found that introduction of an Lkb1
4A4-2/+ mutant background
enhanced performance only in the C155:Htt138Q background,
but had no effect on either C155 or C155:Htt15Q control
backgrounds (Fig. 5E). This suggests that the toxicity effects of
Figure 2. Htt138Q aggregation inhibition screening in primary neural cultures using custom algorithms. (A) Scatter plot indicating the
extent of Htt138Q aggregation following treatment with ,2600 small molecules. Log2 ratio of Htt138Q aggregates (small molecule treated well/
DMSO treated well from the same screen plate) is plotted. The red line denotes two standard deviations from the mean Log2 ratio observed in the
screen data set. Circled wells correspond to compounds that suppress aggregate formation and were subsequently analyzed in downstream
validation studies. (B,C) Representative data set images collected via automated microscopy and analyzed with algorithms. (B) Htt15Q control
cultures have few aggregates, while mutant Htt138Q cultures (C) have numerous aggregates. The exposure time used for image collection was
optimized for Htt aggregate detection, which has a higher signal intensity than soluble Htt. This avoided pixel saturation at the upper end of the
aggregate dynamic range, ensuring accurate aggregate quantification, although soluble Htt is not readily detectable in automated microscopy
images. Image analysis was performed as described in the materials and methods. Scale bar: 200 mm.
doi:10.1371/journal.pone.0023841.g002
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RNAi knockdown, as performed in our primary culture screening
assay, is representative of a hypomorphic situation, and the in vivo
lkb1 rescue studies we conducted were haplo-insufficient, partial
knockdown screening can be advantageous to uncover therapeutic
targets. Full knockdown of lkb1 would not have revealed beneficial
effects, as homozygous lkb1 null mutants are lethal and have cell
polarity defects [41].
To investigate the mechanism of action of Camptothecins in
suppression of Htt138Q neurotoxicity, we performed genetic loss-
Figure 3. Morphological analysis of Htt138Q aggregation inhibitors. (A) P-value scatter plot illustrating the ability of a subset of Htt138Q
aggregation inhibitors to revert neuronal morphology towards Htt15Q controls. Circled compounds are the Camptothecin aggregation inhibitors. For
morphological analysis, neurite (short, medium, long and average neurite length) and neuromere features (small, medium, large, average neuromere
area) were used to compute statistical significance. (B–E) Representative automated microscopy images showing the neuronal morphology profiles
of Drosophila primary neural cultures plated on plastic, optical-bottom, 384-well plates. (C) Htt138Q primary neural cultures have dysmorphic
neuronal profiles relative to Htt15Q controls (B). (D, F) Rescue of Htt138Q mutant morphology by treatment with 10-Hydroxy Camptothecin or Lkb-1
knockdown via RNAi. (E) An example of a small molecule (Okadaic acid) found to suppress Htt138Q aggregation, but which exacerbates the mutant
Htt138Q mutant morphology. Scale bar: 200 mm.
doi:10.1371/journal.pone.0023841.g003
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thecins function as Top1 inhibitors, we reasoned that Top1 RNAi
knockdown in primary cultures should phenocopy Camptothecin
treatment and suppress HD pathology. RNAi knockdown of Top1
or other annotated Drosophila Top genes (Top2, 3a or 3b), either
singularly or in combination, did not suppress Htt aggregation
(Table 3). Knockdown of the Tops did, however, partially revert
the mutant Htt138Q neurite morphology towards controls. To
extend these studies in vivo we introduced a heterozygous Top1 null
allele into the HD model background, but this had no effect on
Htt138Q-induced pupal lethality, as no adult escapers were
observed. Given that Camptothecins have a robust effect on
Htt138Q aggregation inhibition, while Top-knockdown does not,
these results suggest that Camptothecins may act through a Top1-
independent pathway to suppress Htt138Q aggregation.
The compounds that suppress Htt138Q aggregate formation,
and/or rescue neurite morphology in our system, can be
grouped into two classes based on their structures (Figure S1).
The Camptothecins, GW5074, Radicicol, and Etoposide form
one class that have partially overlapping backbone ring-
Table 2. Compounds found to inhibit mutant Htt138Q aggregation and revert primary culture morphology towards Htt15Q
controls*.
I.D. Compound CAS# Function
Htt
Culture
Htt138Q
Aggregate
Log2 ratio
Aggregate
Suppression
Significance**
(p-value)
Morphology
Statistical
Significance***
(p-value) Library
ICCB
Plate I.D.,
Well # Well Conc
1 Camptothecin 7689-03-4 topoisomerase I inhibitor,
antineoplastic
138Q 21.637238 0.00000365 0.151249 BIOMOL2 1791, N06 26 uM
2 Camptothecin 7689-03-4 topoisomerase I inhibitor,
antineoplastic
138Q 21.22608 0.00000927 0.109087 Prestwick 1568, H21 10 uM
3 Camptothecin 7689-03-4 topoisomerase I inhibitor,
antineoplastic
138Q 21.152003 0.00000000 0.06008 NINDS 1921, N08 20 uM
4 Etoposide 33419-42-0 topoisomerase II inhibitor,
antineoplastic
138Q 20.881592 0.00003212 0.003217 Prestwick 1569, O13 6.8 uM
5 10-OH-
Camptothecin
64439-81-2 topoisomerase 1 inhibitor,
antineoplastic
138Q 22.21028 0.00000012 0.00242 BIOMOL2 1791, B06 26 uM
6 Ouabain 630-60-4 Na+/K+-ATPase
inhibitor
138Q 21.050767 0.00000268 0.000246 BIOMOL2 1792, B13 17 uM
7 Proscillaridin A 466-06-8 Na+/K+-ATPase
inhibitor
138Q 20.876806 0.00020794 0.000006 Prestwick 1571, E13 7.5 uM
8 Ethacrynic acid 58-54-8 GST inhibitor 138Q 21.088665 0.00003454 0.000001 Prestwick 1568, D20 13.2 uM
*Compounds listed correspond to hits shown in Figure 3A. Bolded compounds are the circled hits.
**P,0.05 indicates that Htt138Q aggregate formation is inhibited.
***P.0.05 indicate mutant Htt138Q neurite morphology is reverted towards Htt15Q controls.
doi:10.1371/journal.pone.0023841.t002
Table 3. RNAi validation. Effect of Lkb-1 or Top knockdown on Htt138Q aggregate formation and rescue of mutant culture
morphology.
Gene Target dsRNA amplicon Off-targets Htt Culture
Aggregate Suppression
Significance (p-value)*
Morphology Statistical
Significance (p-value)** n=
LKB-1 DRSC16481 0 138Q 0.995894 0.152692 12
LKB-1 DRSC36925 0 138Q 0.730001 0.979141 12
LKB-1 DRSC36926 0 138Q 0.89236 0.702101 12
Top 1 DRSC36056 0 138Q 0.833703 0.428127 12
Top 1 DRSC20295 0 138Q 0.968551 0.015374 12
Top 2 DRSC36057 0 138Q 0.993983 0.208051 12
Top 2 DRSC03459 0 138Q 0.960684 0.35244 12
Top 3a DRSC03460 0 138Q 0.980167 0.102255 12
Top 3a DRSC37672 0 138Q 1 0 12
Top 3b DRSC18724 0 138Q 0.288516 0.331471 12
Mock N/A N/A 138Q 1 0 12
Mock N/A N/A 15Q 0 1 72
*Htt Aggregates. P,0.05 Indicates suppression of Htt138Q aggregate formation.
**P.0.05 indicates mutant Htt138Q neurite morphology is reverted towards Htt15Q controls.
doi:10.1371/journal.pone.0023841.t003
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cillaridin-A form a second class that share a similar steroid-like
backbone. It will be interesting to conduct further structure-
function analysis to determine a minimal architecture that is
required for these compounds to rescue Htt138Q-induced
pathology.
Figure 4. In vitro validation of small molecule screen hits. Confocal microscopy images of primary cultures plated on glass coverslips and
treated with either DMSO (A,B) or test compounds (C,D). Primary neural cultures expressing Htt138Q have numerous aggregates in neurite
processes and surrounding the cell bodies (B), while control Htt15Q expressing cultures do not (A). Htt15Q is soluble and fills most neurite processes.
Treatment of Htt138Q expressing cultures with Camptothecin (C) or 10-OH-Camptothecin (D)a t5 6mM reduces aggregate formation and increases
the proportion of soluble Htt138Q which fills neurite processes. (E) Quantification of altered Htt138Q distribution following Camptothecin treatment.
An increase in the number of Htt138Q pixels/neuronal area (Htt-RFP pixels/neuromere and neurite GFP pixels) is observed in mutant cultures,
suggesting an increase in Htt138Q solubility after drug treatment. * p,0.05, n=4, Scale bar: 100 mm.
doi:10.1371/journal.pone.0023841.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23841Figure 5. In vivo validation of screen hits. (A) Survival frequency scores for HD larvae (Elav
c155-GAL4; UAS-Htt138Q
2/+) after 5-day drug dosing in
liquid culture. (B) Chemical structures of the Camptothecin and 18b-Glycyrrhetinic acid class of small molecules found to rescue Htt138Q toxicity in
vivo.( C–E) Genetic interaction studies to assess the effect of lkb1 kinase reduction on Htt138Q toxicity. (C) Pan-neuronal expression of Htt138Q
1
causes pupal lethality (left) which can be rescued with the introduction of an lkb1 heterozygous background. (D) Quantitative Western blot analysis
demonstrating lkb1-rescued HD adults have normal Htt138Q expression levels. A control deficiency, Df(3L)vin, which reduces Htt138Q expression is
shown for comparison. (E) Lkb1 mutation rescues the climbing behavior of HD flies. 25 day-old Htt138Q flies (C155;UAS-Htt138QmRFP
2) have impaired
climbing behavior as compared to controls. Introduction of an Lkb1
4A4-2 trans-heterozygous mutation into the Htt138Q
2 background improves
climbing ability. * p,0.05.
doi:10.1371/journal.pone.0023841.g005
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We have used Drosophila primary neural cultures isolated from
an HD model to screen for RNAi and small molecule suppressors
of expanded polyQ Htt-induced toxicity. Cultures expressing a
588 amino acid fragment of human Htt containing an expanded
polyQ domain (138Q) display robust cytoplasmic Htt aggregates,
and have dystrophic neurites compared to Htt15Q control
cultures. To identify supressors of expanded polyQ Htt toxicity,
we screened for compounds and RNAi targets that reduce
aggregate formation and revert morphological defects towards
the control state. Our screening resulted in the identification of
lkb1, an upstream kinase regulator of the mTOR/Insulin pathway,
as a suppressor of mutant Htt toxicity. We also identified multiple
compounds that have promising HD therapeutic efficacy: 18b-
Glycyrrhetinic acid, Carbenoxolone, and the Camptothecins. Due
to the efficiency of conducting screens in cell culture, and the
increased physiological relevance of primary neurons, this
methodology represents a powerful approach to identify modifiers
for other neurodegenerative disorders.
LKB-1 knockdown was found to suppress mutant Htt toxicity in
our system, as it rescued the dysmorphic primary neural culture
morphology in vitro and restored viability in vivo. LKB-1 has been
extensively studied, and mutations in the locus result in the Peutz
Jeghers Syndrome (PJS) [42,43]. In Drosophila, loss of LKB-1 in the
embryonic nervous system blocks apoptosis and results in
hyperplasia [44]. How a partial LKB-1 knockdown elicits its
beneficial effect in our system is still uncertain, although decreased
levels of LKB-1 may reduce apoptosis caused by mutant Htt.
LKB-1 lies upstream of many pathways that have previously been
implicated in HD, including the mTOR/autophagy pathway
[25,45,46] and the Insulin/AMPK signaling network [47,48].
Recently our findings were corroborated in vertebrates as
activation of AMPK, the main kinase target of LKB-1, was found
to potentiate striatal neurodegeneration in HD [49].
Several compounds that suppressed mutant Htt toxicity in our
primary culture system have previously been shown to have
neuroprotective effects in mammalian systems, indicating that the
assay with Drosophila primary cultured neurons has translational
capacity. Compound GW5074 inhibited mutant Htt aggregate
formation in our system, and also reduced striatal degeneration in
the NP-3 mouse HD model [28]. Similarly, 18b-Glycyrrhetinic
acid, which rescued HD toxicity in vivo in our Drosophila assays, has
been shown to suppresses neurotoxicity in a PC12 cellular stress
model [34].
By analyzing the molecular structures and mechanisms of action
of the small molecules identified as mutant Htt suppressors, new
avenues to investigate the biology of HD pathogenesis have been
uncovered. 18b-Glycyrrhetinic acid, and Carbenoxolone, which
were used to pharmacologically manipulate LKB-1 dependent
pathways and rescue HD toxicity in vivo, have also been reported
to block gap junction activity [50]. Although this mechanism was
not further investigated, it is an intriguing approach for future
characterization in HD pathology. Recently there have been
several reports that mutant Htt expressed in glia can trigger
neuronal defects [7,51–53]. In addition, postmortem analysis of
HD patient brain samples revealed increased activated astrocytes
and reactive microglia in the striatum and cortex compared to
similar aged non-diseased brains [54]. Gap junctions allow
astrocytes to communicate via elaborate networks, and there is
evidence that cell death signals can be propagated through gap
junction networks [55]. Therefore, modulating gap junction
activity with non-toxic compounds such as 18b-Glycyrrhetinic
acid or Carbenoxolone might have neuroprotective benefits. 18b-
Glycyrrhetinic acid derivatives are particularly interesting because
they have already been evaluated in two clinical trials for other
indications (ClinicalTrials.gov Identifier: NCT00384384 and
NCT00759525), and are widely used as commercial sweeteners.
Recently, an 18b-Glycyrrhetinic acid derivative was found to be
efficacious in the treatment of two mouse models of Amyotrophic
Lateral Scleosis (ALS) and an Alzheimer’s Disease model, further
supporting the potential therapeutic value of this class of
compounds for neurodegenerative diseases [56].
Camptothecins were very effective at suppressing the dystrophic
neuronal profiles and mutant Htt aggregation in our assay.
Camptothecins are potent anti-cancer drugs that block cell
division through several mechanisms including the introduction
of DNA replication-dependant double-stranded breaks which
trigger apoptosis, and down regulation of Top-1 by activation of
proteasome pathways. In quiescent neurons, Camptothecins most
likely cause transcriptional repression as a result of collisions
between RNA polymerase and immobilized Top-1/Camptothecin
complexes linked to the DNA. In our system, the benefit of
Camptothecin treatment could theoretically be related to
decreased Htt transgene expression, although we did not observe
any decrease in Htt-mRFP fluorescence, even after one week of
continuous exposure to the drug. Since targeted knockdown of
mutant Htt via siRNA has been found to be effective at reversing
disease progression in mouse models, small molecule transcrip-
tional repressors may offer another therapeutic avenue to control
HD [57]. Although toxicity issues have been reported in neural
cultures following Camptothecin treatment, we did not observe
morphological defects in our Drosophila HD model [58]. Camp-
tothecins have been reported to regulate a number of different
pathways, including activation of the ubiquitin/proteasome system
and upregulation of mitochondrial biogenesis. These secondary
Camptothecin effects could alleviate toxic Htt cellular stress by
removing toxic Htt species or restoring energy homeostatis [59–
62].
There has been debate in field about the contribution of Htt
aggregates to disease pathology for many years. Several studies
have shown that Htt aggregates accumulate in fine neuronal
processes such as axons and dendrites, and block axon-transport to
negatively impact cell heath [17,63–65]. Real-time imaging
experiments have suggested that soluble Htt, and not aggregates,
correlate better with cellular toxicity [66]. Given this controversy,
we chose not to use aggregate suppression as the sole metric to
identify small molecules and RNAi knockdown probes that have
therapeutic value and included an additional parameter: neurite
morphology. We found that neurite processes are sensitive to
mutant polyQ-expanded Htt and offer a means of identifying
drugs and RNAi knock-downs that have non-specific toxicity
effects. Using this assay we were able to identify compounds and
RNAi knockdowns that have potential therapeutic value. Although
our studies cannot conclusively demonstrate a physiological link
between aggregate inhibition and improved neuronal health, we
did discover compounds that improved neurite morphology in
addition to reducing mutant Htt aggregation, providing anecdotal
evidence that in some cases aggregates may have toxic properties.
Drosophila models of neurodegenerative disease have been a
powerful tool for understanding mechanisms of neurodegeneration
for more than a decade, and have more recently been applied
directly to drug discovery as well [67–74]. Aside from genetic tools
in Drosophila and the host of neurodegenerative disease models
available, it is an attractive model for conducting suppressor
screens given the lack of gene redundancy often observed in
mammals. While single gene knock-down studies often fail to
produce robust phenotypes in mammals, this is not the case in
High-Content Screens for HD Suppressors
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23841Drosophila [75,76]. We have found that the complex neural
morphologies of Drosophila primary cultures can also provide
sensitive information about the general cell physiological status of
a disease model. The algorithms that we have used in this study
can help quantify complex morphologies can also facilitate the
identification of disease modifying genes [23]. Live imaging, as
presented here, has the advantage over traditional cell staining
experiments in that the fine neurite morphology of cultures is
preserved. Detergents and washes needed for immunofluores-
cence-based assays can disrupt fine cellular processes and
introduce artifacts, which reduce assay sensitivity and introduce
noise. Live-cell imaging also makes it possible to collect different
time points in a single experiment, which not only reduces labor
but also enables one to track the effect of a compound or gene
knockdown over time. Because of the ease and speed of
conducting RNAi and compound screens in Drosophila primary
culture systems, this methodology offers an attractive approach to
identify disease-modifying agents for neurodegenerative diseases.
Methods
Primary Cell Culture
Elav
c155-GAL4 virgins were collected en masse and crossed
to either UAS-Htt138QmRFP
1,UAS-mCD8-GFP or UAS-Htt15Qm
RFP
1,UAS-mCD8GFP males to generate embryos for primary
culture preparation. Neuroblasts were isolated as previously
described [22].
Western Blotting
Embyronic lysates (n=4/genotype) were prepared from control
and Htt expressing strains (50 mM Tris, pH 8.0, 150 mM NaCl,
0.1% SDS, 1.0% NP-40 (IgePal), 0.1% sodium deoxycholate plus
protease inhibitors (cOmplete-mini, Roche)), and protein content
was quantified using a BCA kit (Pierce). Protein samples (10 mg/
lane) were analyzed using standard SDS-PAGE/Western blotting
techniques, and quantified using an Odyssey Infrared Imaging
System (Li-Cor). For immunoblotting, antibodies were used at the
following concentrations: mouse anti-Tubulin (6-11B-1, Sigma-
Aldrich T7451) at 1/60,000, mouse anti-human Htt (MAb 2166,
Chemicon) at 1/1,000, and goat-anti-mouse IR800 secondary (LI-
COR 926-32210) at 1/3,000.
Compound screening
Primary cultures were re-suspended directly in Shields and Sang
M3 media (Sigma) supplemented with 10 U/mL penicillin,
10 mg/mL streptomycin, 200 ng/mL insulin, and 5% fetal bovine
serum. 100 nL of compounds from arrayed small-molecule
libraries (NINDS Custom Collection 2, Prestwick1 Collection,
BIOMOL2 ICCB-Longwood Known Bioactives High Concen-
tration, various concentration from 1–15 mM in DMSO) were
applied to 50 mL of cultures 24 hours after plating on optical
bottom 384-well plates (Corning 3712). The neuroblast density
was 18,500 cells/well. The primary screen was carried out in
duplicate and hits were validated with 12 additional replicate
wells.
RNAi Screening
dsRNAs (250 ng/well) were aliquoted onto microscopy plates
and then 10 mL of neuroblasts were applied to a density of 18,500
cells/well. Cultures were incubated for 3 days with dsRNAs to
achieve gene knockdown. Shields and Sang M3 media (Sigma)
supplemented with 10 U/mL penicillin, 10 mg/mL streptomycin,
200 ng/mL insulin, and 5% fetal bovine serum was then added to
cultures to bring assay volume to 50 mL. The Drosophila RNAi
Screening Center (DRSC) whole genome kinase/phosphatase
library (468 genes, 3 amplicons/gene) was screened in duplicate,
and hits were validated using additional dsRNA amplicons
containing no off-targets. For RNAi validation studies, dsRNAs
were synthesized from T7-tailed DNA templates using the
MEGAshortscript T7 transcription kit (Ambion). Synthesized
dsRNAs were purified with RNeasy kits (Qiagen) before use in
cell culture experiments. The T7-tailed oligonucleotides used to
generate DNA templates from w
1118 genomic DNA are as follows:
Lkb-1: DRSC16481 (GCCGTCAAGATCCTGACTA/CTCCG-
CTGGACCAGATG), DRSC36925 (GCAACTCCACGGTGA-
TACCT/ATGCAGGACGTCAGCTTCTT), DRSC36926 (AT-
TGCGGCGAACTTACTTTG/TAATCCTCACCAGGCACA-
CA); Top-1: DRSC36056 (GAGAATGTGCAGGGACAGGT/
GTCGATGAAGTAAAGGGCCA), DRSC20295 (GGAGGAG-
GAGAAGCGTG/GCGCCGCTTGATCATG); Top2: DRSC
36057 (CACAGCGACAGAAGCATCAT/TTCTTGTATTCC-
CTCGTGGC), DRSC3459 (TTTGCCAGAGCGATATCTC/
CCATAGTGGCTCGATCTTTT); Top3a: DRSC3460 (TTAA-
ACGTGGCTGAGAAGAA/GCCCACGCCCTTTTTCA), DR
SC37672(GTGGTCCTGACCGAACAGAT/AGGTTTTGTA-
CCAACCGCTG); Top3b: DRSC18724(GCGGACTTCGGT-
GAGGA/CGCTGGCAGATGTTGTTG).
Microscopy
For high-content screening, mature 7-day old cultures were
imaged with an ImageXpress
MICRO robotic microscope (Molec-
ular Devices, Sunnyvale, CA) using a 106 objective and FITC/
Cy3 filter sets. Images were 139261040 pixels, or 8976670 mi-
crometers. Laser-based autofocusing was used to locate plate
bottoms, and then image-based focusing was used to resolve
fluorescently labeled neurons over a 48 mm range. The GFP and
mRFP channels were imaged in the same focal plane, with
exposure times of 850 and 400 ms respectively. Three sites were
imaged per well for each treatment group, and the screen was
done in duplicate. For confocal microscopy of primary cultures,
neuroblsts were plated on poly-L-lysine coated chambered cover
slips (LabTekII, 0.8 cm
2/well) at 18,300 cells/well in 50 mL
volume. Small molecules were added to cultures 24 hours after
plating, incubated for 7 days, and then imaged with a Leica TCS-
SP2 confocal LSM microscope.
Digital Image Analysis of High Content Screening Data
Sets
Neuronal morphological analysis and Htt aggregate quantifica-
tion for automated microscopy images was performed as
previously described [23,77]. In brief, Htt138Q aggregates were
quantified as the total number of pixels/image with intensity
higher than an empirically set threshold. To quantify neuronal
morphologies, cell body clusters (neuromeres) and neurites were
extracted from images using our custom algorithms [21]. The log2
transformed areas of cell body clusters were found to fit a Gaussian
mixture model (GMM) and therefore were separated into three
bins (small, medium, and large). Absolute counts of neuromeres/
bin were tabulated for all images. Neurite segment lengths were
similarly clustered into three groups (short, medium, and long)
using the K-means method and then quantified. Cell cluster and
neurite counts were converted into percentages to control for any
variation in cell number between wells arising from pipetting
error. Mean neuromere area and neurite length for each image
were also calculated to give a total of eight morphological metrics
for image morphology quantification. For statistical analysis, p-
values for each morphological feature were calculated using a two
sample t-test (e.g. small neuromere feature of Htt138Q drug-
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cultures). The resultant morphological p-values for individual
features were then integrated into a single p-value using the Fisher
method [78] defined by the equation x2~{2Sk
i~1loge pi ðÞ , where
k represents independent tests, pi is the p-value of the i-th feature.
The combined statistic has a x
2 distribution with 2k degrees of
freedom under the joint null hypothesis. This method works well
in cases where the evidence against the null-hypothesis is spread
across different features. Excluded from analysis were compound-
treated wells with ,6 images, out-of-focus images, or images that
lacked cell profiles altogether.
In vivo Rescue studies
For small molecule in vivo rescue studies, Elav
c155; UAS-
Htt138QmRFP
1,UAS-mCD8-GFP/+ 1
st instar larvae were collected
en-masse and dispensed into liquid media (10 larvae/well)
containing different concentrations of test compounds (n=8
replicas/concentration). The cultures were reared at 21uC for 5
days, and the mean number or living Htt138Q larvae (i.e. GFP
+,
Htt138QmRFP
+, and mobile) was tabulated, and expressed as a
percentage of total larvae/well. For genetic rescue studies with
lkb1, two Htt138Q strains were utilized: a strong expressing line,
UAS-Htt138QmRFP
1 which is pharate lethal when crossed to
Elav
c155, and a weaker expressing line, UAS-Htt138QmRFP
2 which
survives to adulthood and is viable for a number of weeks. Using
the strong line, pharate lethality at 25uC was calculated after
lkb1 (lkb1
4B1-11 and lkb1
4A4-2 alleles) was introduced into an
Elav
c155,UAS-Htt/+ background. Lkb1
4B1-11 is a premature
truncation allele (Q98.Stop), and lkb1
4A4-2 is an EMS null allele
(589 b.p. deletion removing 150 b.p. of the 59 UTR, the start
codon and the beginning of the open reading frame). For Top1 in
vivo analysis, Elav
c155,Top
112 recombinants were generated and
crossed to UAS-Htt138QmRFP
1.
Negative Geotaxis Assay
Lkb1
4A4-2 was crossed into the Elav
c155, UAS-Htt138QmRFP
2
which is adult viable and has weaker Htt138Q expression. Virgin
female Drosophila were collected and flipped onto fresh media two
times per week until the start of the assay. 25 day-old flies (10–15
flies/vial, 4 vials/genotype) were gently tapped to the base of vials,
and climbing behavior was video-recorded for 18 seconds (trial).
The percentage of flies to reached the top of a vial was tabulated
and averaged after 4 trails. Vials were back-lit with a light box to
enhance the resolution of the fly climbing trajectories. Statistical
analysis was performed using a t-test.
Supporting Information
Figure S1 Selective compounds tested for their ability to
suppress Htt138Q neuronal toxicity.
(TIF)
Table S1 Compounds found to inhibit Htt138Q aggregate
formation in Drosophila primary neural culture screen.
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Movie S1 Elav
c155-GAL4;UAS-Htt138QmRFP
1/lkb1
4A4-2 rescued
adult Drosophila.W h i l eElav
c155-GAL4;UAS-Htt138QmRFP
1/+ adults
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